Objective: Millions of patients continue to require opioid analgesics for control of moderate to severe chronic pain, which is a disease that affects more Americans than cancer, heart disease, and diabetes combined. Common opioid adverse effects include constipation, sedation, and nausea. A lesser-known sequelae is opioid induced androgen deficiency (OPIAD). The objective of this review was to better characterize the effects of opioids on the endocrine system.
Methods: Published data were evaluated to identify links between opioid use and hypogonadism, as well as to describe proposed physiological mechanisms.
Results: Chronic opioid use may predispose to hypogonadism through alteration of the hypothalamic-pituitary-gonadal axis as well as the hypothalamic-pituitary-adrenal-axis. The resulting hypogonadism and hypotestosteronism may contribute to impaired sexual function, decreased libido, infertility, and osteoporosis- none of which may be clinically recognized as opioid related.
Conclusions: OPIAD is a recognized consequence of long-term opioid therapy. Patients initiated or maintained on opioids should be queried about symptoms that might suggest hypogonadism including irregular menses, reduced libido, depression, fatigue, and hot flashes or night sweats. Some clinicians recommend assessment of baseline testosterone levels prior to initiating therapy. Additional data appear necessary to formulate guidelines regarding the diagnosis and management of OPIAD. Options include, rotating, reducing the dose or type, or cessation of opioid therapy or adding hormonal supplementation in the form of androgen replacement therapy. There are multiple formulations of testosterone available for replacement therapy, which is usually guided by laboratory measurements.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pme.12926 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Persistent opioid use after hospital admission due to trauma.
Pain
February 2025
Department and Graduate Institute of Business Administration, National Taiwan University, Taipei, Taiwan.
Predictors of Participation in Prenatal Substance Use Assessment, Counseling, and Treatment Among Pregnant Individuals in Prenatal Settings Who Use Cannabis.
J Addict Med
November 2024
From the, Kaiser Permanente Washington Health Research Institute, Seattle, WA (GTL); Department of Health Systems and Population Health, University of Washington, Seattle, WA (GTL); Division of Research, Kaiser Permanente Northern California, Oakland, CA (FWC, KCY-W, MBD, CIC); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA (KCY-W, CIC); and Regional Offices, Kaiser Permanente Northern California, Oakland CA (DA, CC, AHA, AE).
Objectives: Assessment and counseling are recommended for individuals with prenatal cannabis use. We examined characteristics that predict prenatal substance use assessment and counseling among individuals who screened positive for prenatal cannabis use in prenatal settings.
Methods: Electronic health record data from Kaiser Permanente Northern California's Early Start perinatal substance use screening, assessment, and counseling program was used to identify individuals with ≥1 pregnancies positive for prenatal cannabis use.
Substructure-Specific Antibodies Against Fentanyl Derivatives.
ACS Nano
January 2025
School of Chemistry and Biochemistry, Georgia Institute of Technology, 901 Atlantic Dr., Atlanta, Georgia 30332, United States.
Structural variants of the synthetic opioid fentanyl are a major threat to public health. Following an investigation showing that many derivatives are poorly detected by commercial lateral flow and related assays, we created hapten conjugate vaccines using an immunogenic virus-like particle carrier and eight synthetic fentanyl derivatives designed to mimic the structural features of several of the more dangerous analogues. Immunization of mice elicited strong antihapten humoral responses, allowing the screening of hundreds of hapten-specific hybridomas for binding strength and specificity.
View Article and Find Full Text PDFProspective evaluation of opioid cessation in patients with suspected Opioid-induced esophageal dysfunction (OIED).
Am J Gastroenterol
January 2025
Neurogastroenterology and Motility Unit, Gastroenterology Department, Institut Clínic de Malalties Digestives i Metabòliques (ICMDM), Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain 08036.
Introduction: The causal relationship between chronic opioid use and esophageal motor dysfunction in symptomatic patients has not been established.
Methods: A prospective before-and-after multicenter study, including chronic active opioid patients referred for esophageal motility tests due to non-obstructive dysphagia.
Results: 37 patients were evaluated, 27 (73%) had criteria of opioid-induced esophageal dysfunction (OIED).
Neonatal Pain Management: Is There An Endocrinal Response?
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Pediatrics, El Menshawy General Hospital, Tanta, Egypt.
Neonates exhibit pain responses characterized by various endocrinal changes, including alterations in cortisone and oxytocin serum levels, as well as physiological and emotional reactions. The administration of neonatal pain management leads to the normalization of endocrine hormones, including cortisone and oxytocin, which are affected by the presence of neonatal pain. Diagnosing neonatal pain is complex; however, effective management is essential.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!